Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Citations Over TimeTop 1% of 2023 papers
Abstract
Vaccines and drugs have helped reduce disease severity and blunt the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susceptibility of natural variants of the main protease [Mpro; 3C-like protease (3CLpro)] of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in Mpro confer resistance to nirmatrelvir (the active component of Paxlovid). An additional clinical-stage inhibitor, ensitrelvir (Xocova), shows a different resistance mutation profile. Importantly, phylogenetic analyses indicate that several of these resistant variants have pre-existed the introduction of these drugs into the human population and are capable of spreading. These results encourage the monitoring of resistance variants and the development of additional protease inhibitors and other antiviral drugs with different mechanisms of action and resistance profiles for combinatorial therapy.
Related Papers
- → HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya(2014)12 cited
- → A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002–2011(2017)4 cited
- → Evolvement of HIV-1 drug resistant mutations in vitro without drug pressure(2010)2 cited
- Analysis on drug resistance of human immunodeficiency virus by means of gene detection(2012)
- → Preliminary Characterization of Protease Inhibitor from Bacteria-Associated with Sponge from Panggang Island, Seribu Islands(2006)